{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:36:47Z","timestamp":1776872207024,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11596-021-2373-7","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T01:02:54Z","timestamp":1624582974000},"page":"474-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function"],"prefix":"10.1007","volume":"41","author":[{"given":"Shao-long","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-hang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-mei","family":"Que","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-ming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"issue":"2","key":"2373_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0268-960X(99)90014-0","volume":"13","author":"AD Clark","year":"1999","unstructured":"Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev, 1999,13(2):79\u201390","journal-title":"Blood Rev"},{"issue":"6","key":"2373_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1053\/j.ajkd.2011.12.028","volume":"59","author":"SH Nasr","year":"2012","unstructured":"Nasr SH, Valeri AM, Sethi S, et al. Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney Biopsies. Am J Kidney Dis, 2012,59(6):786\u2013794","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2373_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1525-139X.2009.00582.x","volume":"22","author":"G Cohen","year":"2009","unstructured":"Cohen G, Horl WH. Free Immunoglobulin Light Chains as a Risk Factor in Renal and Extrarenal Complications. Semin Dialysis, 2009,22(4):369\u2013372","journal-title":"Semin Dialysis"},{"issue":"8","key":"2373_CR4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/leu.2008.131","volume":"22","author":"MA Dimopoulos","year":"2008","unstructured":"Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia, 2008,22(8):1485\u20131493","journal-title":"Leukemia"},{"issue":"2","key":"2373_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/10428190601126602","volume":"48","author":"V Eleutherakis-Papaiakovou","year":"2007","unstructured":"Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance. Leuk Lymphoma, 2007,48(2):337\u2013341","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2373_CR6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/leu.2015.15","volume":"29","author":"R Khan","year":"2015","unstructured":"Khan R, Apewokin S, Grazziutti M, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. Leukemia, 2015,29(5):1195\u20131201","journal-title":"Leukemia"},{"issue":"1","key":"2373_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-019-0819-1","volume":"12","author":"DL Liu","year":"2019","unstructured":"Liu DL. CAR-T \u201cthe living drugs\u201d, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J Hematol Oncol, 2019,12(1):113","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2373_CR8","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1182\/bloodadvances.2020004017","volume":"5","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin GR, Rooney A, Balmaceda N, et al. Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Adv, 2021,5(4):1097\u20131101","journal-title":"Blood Adv"},{"issue":"1","key":"2373_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang TB, Liu DL. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol, 2020,13(1):125","journal-title":"J Hematol Oncol"},{"issue":"18","key":"2373_CR10","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med, 2019,380(18):1726\u20131737","journal-title":"N Engl J Med"},{"issue":"10","key":"2373_CR11","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1016\/j.clml.2019.09.083","volume":"19","author":"SG Hao","year":"2019","unstructured":"Hao SG, Jin J, Yu K, et al. CT053, Anti-BCMA CAR T-cell therapy for Relapsed\/Refractory Multiple Myeloma: Proof of Concept results from a Phase I Study. Clin Lymphoma Myeloma Leuk, 2019,19(10):E54\u2013E55","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2373_CR12","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1002\/ctm2.346","volume":"11","author":"C Li","year":"2021","unstructured":"Li C, Cao W, Que Y, et al. A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med, 2021,11(3):e346","journal-title":"Clin Transl Med"},{"issue":"21","key":"2373_CR13","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang D, Wang J, Hu G, et al. A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed\/Refractory Multiple Myeloma. Blood, 2021,137(21):2890\u20132901","journal-title":"Blood"},{"issue":"12","key":"2373_CR14","doi-asserted-by":"publisher","first-page":"E538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol, 2014,15(12):E538\u2013E548","journal-title":"Lancet Oncol"},{"issue":"1","key":"2373_CR15","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41598-018-38129-7","volume":"9","author":"JC Walk","year":"2019","unstructured":"Walk JC, Ayati BP, Holstein SA. Modeling the Effects of Multiple Myeloma on Kidney Function. Sci Rep-Uk, 2019,9(1):1726","journal-title":"Sci Rep-Uk"},{"issue":"7","key":"2373_CR16","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3324\/haematol.2015.137083","volume":"101","author":"KC Weisel","year":"2016","unstructured":"Weisel KC, Dimopoulos MA, Moreau P, et al. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low \u2014 dose dexamethasone versus high \u2014 dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica, 2016,101(7):872\u2013878","journal-title":"Haematologica"},{"issue":"1","key":"2373_CR17","doi-asserted-by":"publisher","first-page":"9011","DOI":"10.1038\/s41598-018-27411-3","volume":"8","author":"X Chen","year":"2018","unstructured":"Chen X, Wang ZQ, Zhu GY, et al. The references level of cadmium intake for renal dysfunction in a Chinese population. Sci Rep-Uk, 2018,8(1):9011","journal-title":"Sci Rep-Uk"},{"issue":"1","key":"2373_CR18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1515\/labmed-2020-0115","volume":"45","author":"BX Liu","year":"2021","unstructured":"Liu BX, Lu F, Lin J, et al. Correlations of serum beta 2-microglobulin level with disease activity and renal involvement in patients with systemic lupus erythematosus. J Lab Med, 2021,45(1):13\u201318","journal-title":"J Lab Med"},{"issue":"9","key":"2373_CR19","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1681\/ASN.V991723","volume":"9","author":"T Miyata","year":"1998","unstructured":"Miyata T, Jadoul M, Kurokawa K, et al. beta-2 microglobulin in renal disease. J Am Soc Nephrol, 1998,9(9):1723\u20131735","journal-title":"J Am Soc Nephrol"},{"key":"2373_CR20","first-page":"344","volume":"28","author":"F Rainone","year":"2013","unstructured":"Rainone F, Merlino L, Ritchie JP, et al. Multiple Myeloma with Acute Kidney Injury Is the Expression of a More Aggressive Disease. A 10 Year Single Renal Center Experience. Nephrol Dial Transpl, 2013,28:344\u2013344","journal-title":"Nephrol Dial Transpl"},{"issue":"33","key":"2373_CR21","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. J Clin Oncol, 2010,28(33): 4976\u20134984","journal-title":"J Clin Oncol"},{"issue":"2","key":"2373_CR22","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41375-020-0868-z","volume":"35","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Leleu X, Moreau P, et al. Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia, 2021,35(2):562\u2013572","journal-title":"Leukemia"},{"issue":"6","key":"2373_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s12185-015-1771-7","volume":"101","author":"DB Zhou","year":"2015","unstructured":"Zhou DB, Yu L, Du X, et al. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment. Int J Hemato, 2015,101(6):569\u2013577","journal-title":"Int J Hemato"},{"issue":"20","key":"2373_CR24","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1200\/JCO.2017.76.1742","volume":"36","author":"M Dimopoulos","year":"2018","unstructured":"Dimopoulos M, Weisel K, van de Donk N, et al. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. J Clin Oncol, 2018,36(20):2035\u20132043","journal-title":"J Clin Oncol"},{"issue":"4","key":"2373_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/cancers12040921","volume":"12","author":"HM Witte","year":"2020","unstructured":"Witte HM, Bonorden B, Riecke A, et al. The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation. Cancers, 2020,12(4):921","journal-title":"Cancers"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-021-2373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-021-2373-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-021-2373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T08:56:43Z","timestamp":1699174603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-021-2373-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["2373"],"URL":"https:\/\/doi.org\/10.1007\/s11596-021-2373-7","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"16 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declared no conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}